Viruses as antitumor weapons: Defining conditions for tumor remission

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3501-3507

  Wodarz, D ^a  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; HEAD AND NECK CANCER; IMMUNE RESPONSE; IMMUNOSTIMULATION; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRUSES;

EID: 0035870287     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Replicating viruses as selective cancer therapeutics
2. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
3. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
4. New molecular targets for cancer therapy
5. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
6. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53
7. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
8. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
9. ONYX-015: Clinical data are encouraging
10. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
11. Is cancer dangerous to the immune system?
12. An innate sense of danger
13. Immune surveillance against a solid tumor fails because of immunological ignorance
14. Problem solving for tumor immunotherapy
15. Target cell limited and immune control models of HIV infection: A comparison
16. CTL abundance and virus load in HIV- I and HTLV-1
17. A reaction-diffusion model of cancer invasion
18. Application of competition theory to tumour growth: Implications for tumour biology and treatment
19. Modeling immunotherapy of the tumor-immune interaction
20. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
21. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: An intravital microscopic study in mice
22. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
23. Tumor dormancy: Not so sleepy after all
24. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
25. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
26. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients